Trending: AbbVie to Buy Cerevel for $45 a Share
December 07 2023 - 10:27AM
Dow Jones News
9:57 ET--AbbVie is one of the most mentioned companies in the
U.S. across all news items in the last 12 hours, according to
Factiva data. AbbVie will acquire neuroscience-drug maker Cerevel
Therapeutics for $45 a share, giving the company an equity value of
about $8.7 billion. The deal is AbbVie's second major acquisition
in the last two weeks, after the pharmaceutical giant said Nov. 30
it would acquire ImmunoGen for $10 billion. Cerevel is developing
potential candidates to treat schizophrenia, Parkinson's disease
and mood disorders. AbbVie said the deal complements its existing
neuroscience portfolio. Dow Jones & Co. owns Factiva.
(chris.wack@wsj.com)
(END) Dow Jones Newswires
December 07, 2023 10:12 ET (15:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024
